Ginkgo Bioworks Holdings Inc vs SPDR Gold Trust — how do they compare? Ginkgo Bioworks Holdings Inc trades at $7.4 (market cap $505.73M), while SPDR Gold Trust trades at $405.59. The key difference: SPDR Gold Trust is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | GLD | |
|---|---|---|
Market Cap | $505.73M | — |
Sector | Health | — |
52-Week High | $16.14 | $495.90 |
52-Week Low | $5.48 | $305.27 |
Enterprise Value | $607.68M | — |
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $7.29, down 4.71% with bearish technical signals. The company reported Q2 2026 revenue of $20 million, down 48% year-over-year, continuing its strategic pivot to autonomous labs. Despite beating EPS expectations in two of the last three quarters, DNA shows negative profitability with -219.6% net income margin and negative cash flow. Analyst sentiment is mixed with 45% buy ratings but significant institutional selling pressure.
DNA faces substantial execution risk during its business transition, with declining revenue and persistent losses offset by potential in autonomous laboratory technology. The stock's current valuation at 3.61x sales appears stretched given negative earnings, requiring successful operational turnaround for sustainable recovery. Near-term catalysts depend on revenue stabilization and cost management improvements.
GLD, the SPDR Gold Shares ETF, trades at $405.25, up 0.65% today, reflecting strong momentum as gold benefits from cooling U.S. inflation data and safe-haven demand. The technical outlook is bullish with moving averages supporting upward trends, though oscillators signal overbought conditions. Recent news highlights gold's resilience amid geopolitical tensions and central bank buying, with spot gold surpassing $4,438 per ounce after July's CPI report showed a 2.5% annual core increase (Kitco, 2026-08-12).
The outlook for GLD remains positive driven by macroeconomic support, but risks include potential Fed policy shifts and profit-taking pressure. Investors may see opportunities in gold's role as a hedge, though high RSI levels suggest near-term volatility. Key resistance at $407 could test further gains, while support lies at $396.
Trailing returns across standard periods
Latest headlines on both assets
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →GLD is the largest physically backed gold ETF in the world. It offers investors a cost-efficient and secure way to track the price of gold bullion without the need for physical storage.
Read more on GLD →